| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3fca95eab9966c5b4364e0cf227a341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82e5a274e96e89ce8a240a0055e29b9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0e4a8e69c514c5513a6298007f0b7da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15fa9a03b326bfa7edcea43d0b8691aa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-194 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 |
| filingDate |
2001-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14dbfac5ab9270fee036e390340e1b36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f3e13bf817f982add6f0428dc9f0def
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96298427599a87f4e57969116e3817be |
| publicationDate |
2003-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0202190-A3 |
| titleOfInvention |
Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| abstract |
The present invention generally relates to the field of treating degenerative disease by administering a pharmaceutically effective amount of a compound that elevates glutathione or at least one Phase II detoxification enzyme in diseased tissue. The present invention also relates to a pharmaceutical composition useful for the treatment of degenerative diseases, as well as a method of identifying agents that modulate intracellular levels of glutathione or intracellular levels of at least one Phase II enzyme in neuronal cells. |
| priorityDate |
2000-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |